INTRODUCTION — The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with melanoma, both for primary treatment of locoregional disease, and for treatment of advanced disease. This is not an exhaustive list; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with melanoma. Additional regimens may be added over time, particularly as treatment for melanoma evolves.
This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with melanoma. Clinicians should refer to the individual disease-oriented topic review that discusses the use of these protocols in appropriate clinical situations.
These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.
Unresectable or metastatic disease
Nivolumab plus ipilimumab followed by nivolumab monotherapy — (table 1)
Nivolumab monotherapy — (table 2)
Pembrolizumab monotherapy — (table 3)
Locoregionally advanced disease
Adjuvant nivolumab monotherapy — (table 4)
Adjuvant pembrolizumab monotherapy — (table 5)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟